182 related articles for article (PubMed ID: 27055664)
1. Differences of cytomegalovirus diseases between kidney and hematopoietic stem cell transplant recipients during preemptive therapy.
Kim T; Lee YM; Lee SO; Choi SH; Kim YS; Woo JH; Sung H; Jung JH; Shin S; Kim YH; Kang YA; Lee YS; Lee JH; Lee JH; Lee KH; Park SK; Han DJ; Kim SH
Korean J Intern Med; 2016 Sep; 31(5):961-70. PubMed ID: 27055664
[TBL] [Abstract][Full Text] [Related]
2. Paradoxical rising cytomegalovirus antigenemia during preemptive ganciclovir therapy in hematopoietic stem cell transplant recipients: incidence, risk factors, and clinical outcomes.
Park SY; Lee SO; Choi SH; Kim YS; Woo JH; Sung H; Kim MN; Kim DY; Lee JH; Lee JH; Lee KH; Kim SH
J Clin Microbiol; 2011 Dec; 49(12):4179-84. PubMed ID: 22031700
[TBL] [Abstract][Full Text] [Related]
3. Cytomegalovirus infections in lung and hematopoietic cell transplant recipients in the Organ Transplant Infection Prevention and Detection Study: A multi-year, multicenter prospective cohort study.
Avery RK; Silveira FP; Benedict K; Cleveland AA; Kauffman CA; Schuster MG; Dubberke ER; Husain S; Paterson DL; Chiller T; Pappas P
Transpl Infect Dis; 2018 Jun; 20(3):e12877. PubMed ID: 29512935
[TBL] [Abstract][Full Text] [Related]
4. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.
Witzke O; Hauser IA; Bartels M; Wolf G; Wolters H; Nitschke M;
Transplantation; 2012 Jan; 93(1):61-8. PubMed ID: 22094954
[TBL] [Abstract][Full Text] [Related]
5. Cytomegalovirus prevention strategies in seropositive kidney transplant recipients: an insight into current clinical practice.
Fernández-Ruiz M; Arias M; Campistol JM; Navarro D; Gómez-Huertas E; Gómez-Márquez G; Díaz JM; Hernández D; Bernal-Blanco G; Cofan F; Jimeno L; Franco-Esteve A; González E; Moreso FJ; Gómez-Alamillo C; Mendiluce A; Luna-Huerta E; Aguado JM;
Transpl Int; 2015 Sep; 28(9):1042-54. PubMed ID: 25864986
[TBL] [Abstract][Full Text] [Related]
6. Preemptive therapy is not adequate for prevention of cytomegalovirus disease in pancreas-kidney transplant recipients.
López-Medrano F; Rueda B; Lizasoain M; Juan RS; Folgueira D; Andrés A; Morales JM; Jiménez C; Meneu JC; Aguado JM
Transpl Infect Dis; 2009 Oct; 11(5):400-4. PubMed ID: 19570139
[TBL] [Abstract][Full Text] [Related]
7. Preemptive ganciclovir therapy in cytomegalovirus-seropositive renal transplants recipients.
Conti DJ; Freed BM; Singh TP; Gallichio M; Gruber SA; Lempert N
Arch Surg; 1995 Nov; 130(11):1217-21; discussion 1221-2. PubMed ID: 7487465
[TBL] [Abstract][Full Text] [Related]
8. Prophylaxis versus preemptive therapy for cytomegalovirus disease in high-risk liver transplant recipients.
Bodro M; Sabé N; Lladó L; Baliellas C; Niubó J; Castellote J; Fabregat J; Rafecas A; Carratalà J
Liver Transpl; 2012 Sep; 18(9):1093-9. PubMed ID: 22532316
[TBL] [Abstract][Full Text] [Related]
9. Cytomegalovirus High-risk Kidney Transplant Recipients Show No Difference in Long-term Outcomes Following Preemptive Versus Prophylactic Management.
Blom KB; Birkeland GK; Midtvedt K; Jenssen TG; Reisæter AV; Rollag H; Hartmann A; Sagedal S; Sjaastad I; Tylden G; Njølstad G; Nilsen E; Christensen A; Åsberg A; Birkeland JA
Transplantation; 2023 Aug; 107(8):1846-1853. PubMed ID: 37211633
[TBL] [Abstract][Full Text] [Related]
10. Preemptive versus sequential prophylactic-preemptive treatment regimens for cytomegalovirus in renal transplantation: comparison of treatment failure and antiviral resistance.
van der Beek MT; Berger SP; Vossen AC; van der Blij-de Brouwer CS; Press RR; de Fijter JW; Claas EC; Kroes AC
Transplantation; 2010 Feb; 89(3):320-6. PubMed ID: 20145523
[TBL] [Abstract][Full Text] [Related]
11. Impact of a preemptive strategy after 3 months of valganciclovir cytomegalovirus prophylaxis in kidney transplant recipients.
Boillat Blanco N; Pascual M; Venetz JP; Nseir G; Meylan PR; Manuel O
Transplantation; 2011 Jan; 91(2):251-5. PubMed ID: 21099744
[TBL] [Abstract][Full Text] [Related]
12. Impact of Preemptive Therapy for Cytomegalovirus on Toxicities after Allogeneic Hematopoietic Cell Transplantation in Clinical Practice: A Retrospective Single-Center Cohort Study.
Zavras P; Su Y; Fang J; Stern A; Gupta N; Tang Y; Raval A; Giralt S; Perales MA; Jakubowski AA; Papanicolaou GA
Biol Blood Marrow Transplant; 2020 Aug; 26(8):1482-1491. PubMed ID: 32315708
[TBL] [Abstract][Full Text] [Related]
13. Preemptive anti-cytomegalovirus therapy in high-risk (donor-positive, recipient-negative cytomegalovirus serostatus) kidney transplant recipients.
Hasegawa J; Hatakeyama S; Wakai S; Omoto K; Okumi M; Tanabe K; Mieno M; Shirakawa H
Int J Infect Dis; 2017 Dec; 65():50-56. PubMed ID: 28986314
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic cell transplantation.
Green ML; Leisenring W; Stachel D; Pergam SA; Sandmaier BM; Wald A; Corey L; Boeckh M
Biol Blood Marrow Transplant; 2012 Nov; 18(11):1687-99. PubMed ID: 22683614
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for late-onset cytomegalovirus disease in donor seropositive/recipient seronegative kidney transplant recipients who receive antiviral prophylaxis.
Boudreault AA; Xie H; Rakita RM; Scott JD; Davis CL; Boeckh M; Limaye AP
Transpl Infect Dis; 2011 Jun; 13(3):244-9. PubMed ID: 21414119
[TBL] [Abstract][Full Text] [Related]
16. Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial.
Boeckh M; Nichols WG; Chemaly RF; Papanicolaou GA; Wingard JR; Xie H; Syrjala KL; Flowers ME; Stevens-Ayers T; Jerome KR; Leisenring W
Ann Intern Med; 2015 Jan; 162(1):1-10. PubMed ID: 25560711
[TBL] [Abstract][Full Text] [Related]
17. Cytomegalovirus Infection Incidence and Risk Factors Across Diverse Hematopoietic Cell Transplantation Platforms Using a Standardized Monitoring and Treatment Approach: A Comprehensive Evaluation from a Single Institution.
Melendez-Munoz R; Marchalik R; Jerussi T; Dimitrova D; Nussenblatt V; Beri A; Rai K; Wilder JS; Barrett AJ; Battiwalla M; Childs RW; Fitzhugh CD; Fowler DH; Fry TJ; Gress RE; Hsieh MM; Ito S; Kang EM; Pavletic SZ; Shah NN; Tisdale JF; Gea-Banacloche J; Kanakry CG; Kanakry JA
Biol Blood Marrow Transplant; 2019 Mar; 25(3):577-586. PubMed ID: 30342913
[TBL] [Abstract][Full Text] [Related]
18. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J
Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888
[TBL] [Abstract][Full Text] [Related]
19. Increased incidence of herpes zoster in the setting of cytomegalovirus preemptive therapy after kidney transplantation.
Ko GB; Kim T; Kim SH; Choi SH; Kim YS; Woo JH; Kim YH; Park JB; Lee SK; Park SK; Park JS; Han DJ; Lee SO
Transpl Infect Dis; 2013 Aug; 15(4):416-23. PubMed ID: 23676124
[TBL] [Abstract][Full Text] [Related]
20. Half-dose ganciclovir preemptive treatment of cytomegalovirus infection after pediatric allogeneic hematopoietic stem cell transplantation.
Ju HY; Kang HJ; Hong CR; Lee JW; Kim H; Park KD; Shin HY; Park JD; Choi EH; Lee HJ; Ahn HS
Transpl Infect Dis; 2016 Jun; 18(3):396-404. PubMed ID: 27041364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]